Compare LCTX & NATH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LCTX | NATH |
|---|---|---|
| Founded | 1990 | 1916 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Restaurants |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 393.9M | 397.6M |
| IPO Year | N/A | N/A |
| Metric | LCTX | NATH |
|---|---|---|
| Price | $1.68 | $95.22 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 4 | 0 |
| Target Price | ★ $4.25 | N/A |
| AVG Volume (30 Days) | ★ 1.3M | 49.8K |
| Earning Date | 11-06-2025 | 11-06-2025 |
| Dividend Yield | N/A | ★ 2.10% |
| EPS Growth | N/A | ★ 4.02 |
| EPS | N/A | ★ 5.56 |
| Revenue | $10,816,000.00 | ★ $154,991,000.00 |
| Revenue This Year | $5.24 | N/A |
| Revenue Next Year | $126.78 | N/A |
| P/E Ratio | ★ N/A | $17.14 |
| Revenue Growth | ★ 24.05 | 7.82 |
| 52 Week Low | $0.37 | $75.15 |
| 52 Week High | $2.09 | $118.50 |
| Indicator | LCTX | NATH |
|---|---|---|
| Relative Strength Index (RSI) | 46.00 | 47.62 |
| Support Level | $1.69 | $88.67 |
| Resistance Level | $1.79 | $97.34 |
| Average True Range (ATR) | 0.08 | 3.30 |
| MACD | -0.00 | 0.76 |
| Stochastic Oscillator | 43.75 | 71.64 |
Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline is based on two platform technologies including cell replacement and cell/drug delivery. Lineage Cell's product candidate is OpRegen, a retinal pigment epithelium transplant therapy for the treatment of dry age-related macular degeneration, OPC1, an oligodendrocyte progenitor cell therapy for acute spinal cord injuries, and VAC2, allogeneic cancer immunotherapy of antigen-presenting dendritic cells for non-small cell lung cancer, ANP1, an allogeneic auditory neuron progenitor cells transplant for hearing loss, and PNC1, an allogeneic photoreceptor cell transplant for vision loss.
Nathan's Famous Inc is an owner of fast food franchises in the United States. The company's reportable segment includes the Branded Product Program, Product licensing, Restaurant operations and Corporate. Branded Product Program derives revenue principally from the sale of hot dog products either directly to foodservice operators or to various foodservice distributors who resell the products to foodservice operators. It generates maximum revenue from the Branded Product Program segment. Geographically, it derives a majority of revenue from the United States.